# US 2006/0079471 A1 · Snornai-small nucleolar rna degradation by rna interference in trypanosomatids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0079471 A1
- Document ID: US20060079471A1
- Status: Published application
- Kind: A1
- Application number: 10/544,066
- Filed: 2005-08-02
- Published: 2006-04-13
- Earliest claimed: 2003-02-04
- Assignees: Bar-llan University
- Inventors: Shulamit Michaeli
- Web page: https://patentgrep.com/patent/US20060079471A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- C07H 21/02: with ribosyl as saccharide radical
- C07H 21/04: with deoxyribosyl as saccharide radical
- C12N 2310/111: spanning the whole gene, or a large part of it
- C12N 2310/14: interfering nucleic acids [NA]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

Polynucleotides and a method suitable for downregulation of small nuclear RNA which can be used to treat diseases associated with activity of small nuclear RNA are provided. Specifically, the present invention can be used to downregulate snoRNA molecules or box H/ACA-containing RNA molecules which are involved in diseases such as cancer.

## Claims

### Claim 1

An isolated polynucleotide comprising a nucleic acid sequence selected suitable for inducing RNAi-mediated degradation of a small nuclear RNA.

### Claim 2 (depends on 1)

The isolated polynucleotide of claim 1, wherein said small nuclear RNA is a snoRNA.

### Claim 3 (depends on 1)

The isolated polynucleotide of claim 1, wherein said small nuclear RNA is a box C/D-containing RNA, and/or a box H/ACA-containing RNA.

### Claim 4 (depends on 1)

The isolated polynucleotide of claim 1, wherein said nucleic acid sequence contains a sequence at least 75% identical to the polynucleotide set forth by SEQ ID NO:14, 18, 29, 31, 34, 37, 38, or 42 as determined using the BlastN software of the National Center of Biotechnology Information (NCBI) using default parameters.

### Claim 5 (depends on 1)

The isolated polynucleotide of claim 1, wherein said nucleic acid sequence contains a sequence at least 75% identical to the polynucleotide set forth by SEQ ID NO:25, 28, 30, 32, 33, or 36 as determined using the BlastN software of the National Center of Biotechnology Information (NCBI) using default parameters.

### Claim 6 (depends on 2)

The isolated polynucleotide of claim 2, wherein said snoRNA is selected from the group consisting of U3 snoRNA, U8 snoRNA, snoRNA-2, h1 snoRNA, H2 snoRNA, B5 C/D snoRNA, h3 snoRNA, B2 snoRNA, SLA1 RNA, snoRNA 270, TBC4 snoRNA, TBH1 snoRNA, snoRNA 92, G2 snoRNA, U14 snoRNA, HBII-52 snoRNA, and HBII-85 snoRNA.

### Claim 7 (depends on 3)

The isolated polynucleotide of claim 3, wherein said box H/ACA-containing RNA is selected from the group consisting of mouse TER and human TER.

### Claim 8 (depends on 1)

The isolated polynucleotide of claim 1, wherein said nucleic acid sequence is double stranded and includes at least 15 and no more than 30 nucleic acids.

### Claim 9 (depends on 1)

A nucleic acid construct capable of expressing the isolated polynucleotide of claim 1 in a cell.

### Claim 10 (depends on 9)

The nucleic acid construct of claim 9, further comprising a selection marker gene.

### Claim 11 (depends on 10)

The nucleic acid construct of claim 10, wherein said isolated polynucleotide is expressed in a reverse orientation to said selection marker gene.

### Claim 12 (depends on 9)

The nucleic acid construct of claim 9, wherein the nucleic acid construct includes two promoters flanking the isolated polynucleotide, whereas each promoter is capable of directing transcription of a specific strand of the isolated polynucleotide in said cell.

### Claim 13 (depends on 12)

The nucleic acid construct of claim 12, wherein each promoter is independently selected from the group consisting of T7 promoter, SP6 promoter, T3 promoter, CMV promoter, SV40 promoter, adenovirus major late promoter, Rous sarcoma virus promoter.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the isolated polynucleotide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 15

A method of downregulating a level of small nuclear RNA in a cell, the method comprising providing to the cell a polynucleotide having a nucleic acid sequence selected suitable for inducing RNAi-mediated degradation of the small nuclear RNA thereby downregulating the level of the small nuclear RNA in the cell.

### Claim 16 (depends on 15)

The method of claim 15, wherein said small nuclear RNA is a snoRNA.

### Claim 17 (depends on 15)

The method of claim 15, wherein said small nuclear RNA is a box C/D-containing RNA, and/or a box H/ACA-containing RNA.

### Claim 18 (depends on 15)

The method of claim 15, wherein said nucleic acid sequence contains a sequence at least 75% identical to the polynucleotide set forth by SEQ ID NO: 14, 18, 29, 31, 34, 37, 38, or 42 as determined using the BlastN software of the National Center of Biotechnology Information (NCBI) using default parameters.

### Claim 19 (depends on 15)

The method of claim 15, wherein said nucleic acid sequence contains a sequence at least 75% identical to the polynucleotide set forth by SEQ ID NO:25, 28, 30, 32, 33, or 36 as determined using the BlastN software of the National Center of Biotechnology Information (NCBI) using default parameters.

### Claim 20 (depends on 16)

The method of claim 16, wherein said snoRNA is selected from the group consisting of U3 snoRNA, U8 snoRNA, snoRNA-2, h1 snoRNA, H2 snoRNA, B5 C/D snoRNA, h3 snoRNA, B2 snoRNA, SLA1 RNA, snoRNA 270, TBC4 snoRNA, TBH1 snoRNA, snoRNA 92, G2 snoRNA, U14 snoRNA, HBII-52 snoRNA, and HBII-85 snoRNA.

### Claim 21 (depends on 17)

The method of claim 17, wherein said box H/ACA-containing RNA is selected from the group consisting of mouse TER and human TER.

### Claim 22 (depends on 15)

The method of claim 15, wherein said nucleic acid sequence is double stranded and includes at least 15 and no more than 30 nucleic acids.

### Claim 23 (depends on 15)

The method of claim 15, wherein said providing is effected by introducing into the cell a nucleic acid construct capable of expressing said polynucleotide.

### Claim 24 (depends on 23)

The method of claim 23, wherein said nucleic acid construct further comprising a selection marker gene.

### Claim 25 (depends on 24)

The method of claim 24, wherein said polynucleotide is expressed in a reverse orientation to said selection marker gene.

### Claim 26 (depends on 23)

The method of claim 23, wherein the nucleic acid construct includes two promoters flanking the isolated polynucleotide, whereas each promoter is capable of directing transcription of a specific strand of the isolated polynucleotide in said cell.

### Claim 27 (depends on 26)

The method of claim 26, wherein each promoter is independently selected from the group consisting of T7 promoter, SP6 promoter, T3 promoter, CMV promoter, SV40 promoter, adenovirus major late promoter, Rous sarcoma virus promoter.

### Claim 28 (depends on 22)

The method of claim 22, wherein said providing is effected by administering to the cell said double stranded nucleic acid sequence.

### Claim 29

A method of treating a disease characterized by abnormal expression or activity of a biomolecule, wherein the biomolecule includes, associates with, synthesized via or modified by a small nuclear RNA, the method comprising providing to cells of an individual having the disease a polynucleotide having a nucleic acid sequence selected suitable for inducing RNAi-mediated degradation of the small nuclear RNA, thereby downregulating the level of the small nuclear RNA in said cells and treating the disease.

### Claim 30 (depends on 29)

The method of claim 29, wherein said small nuclear RNA is a snoRNA.

### Claim 31 (depends on 29)

The method of claim 29, wherein said small nuclear RNA is a box C/D-containing RNA, and/or a box H/ACA-containing RNA.

### Claim 32 (depends on 29)

The method of claim 29, wherein said nucleic acid sequence contains a sequence at least 75% identical to the polynucleotide set forth by SEQ ID NO:14, 18, 29, 31, 34, 37, 38, or 42 as determined using the BlastN software of the National Center of Biotechnology Information (NCBI) using default parameters.

### Claim 33 (depends on 29)

The method of claim 29, wherein said nucleic acid sequence contains a sequence at least 75% identical to the polynucleotide set forth by SEQ ID NO:25, 28, 30, 32, 33, or 36 as determined using the BlastN software of the National Center of Biotechnology Information (NCBI) using default parameters.

### Claim 34 (depends on 30)

The method of claim 30, wherein said snoRNA is selected from the group consisting of U3 snoRNA, U8 snoRNA, snoRNA-2, h1 snoRNA, H2 snoRNA, B5 C/D snoRNA, h3 snoRNA, B2 snoRNA, SLA1 RNA, snoRNA 270, TBC4 snoRNA, TBH1 snoRNA, snoRNA 92, G2 snoRNA, U14 snoRNA, HBII-52 snoRNA, and HBII-85 snoRNA.

### Claim 35 (depends on 31)

The method of claim 31, wherein said box H/ACA-containing RNA is selected from the group consisting of mouse TER and human TER.

### Claim 36

The method of claim .29, wherein said nucleic acid sequence is double stranded and includes at least 15 and no more than 30 nucleic acids.

### Claim 37 (depends on 29)

The method of claim 29, wherein said providing is effected by introducing into said cells of said individual a nucleic acid construct capable of expressing said polynucleotide.

### Claim 38 (depends on 37)

The method of claim 37, wherein said nucleic acid construct further comprising a selection marker gene.

### Claim 39 (depends on 38)

The method of claim 38, wherein said polynucleotide is expressed in a reverse orientation to said selection marker gene.

### Claim 40 (depends on 37)

The method of claim 37, wherein said nucleic acid construct includes two promoters flanking said polynucleotide, whereas each promoter is capable of directing transcription of a specific strand of said polynucleotide in said cells of said individual.

### Claim 41 (depends on 40)

The method of claim 40, wherein each promoter is independently selected from the group consisting of T7 promoter, SP6 promoter, T3 promoter, CMV promoter, SV40 promoter, adenovirus major late promoter, Rous sarcoma virus promoter.

### Claim 42 (depends on 36)

The method of claim 36, wherein said providing is effected by administering to said cells said double stranded nucleic acid sequence.
